Efficacy of zoledronate or denosumab for advanced non small cell lung cancer patients harboring EGFR mutations.
Phase of Trial: Phase IV
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2017 New trial record